We find subtype-specific positioning for SP100, TGFB3 and LMNA. The direction in which SP100 and TGFB3 reposition, compared to benign tissue, distinguishes low and intermediate/high Gleason score cancers, whereas LMNA repositions in many non-metastatic cancers but not in metastatic cancers. This evidence concerns the gene TGFB3 and cancer.